Document is current
Any future updates will be listed below
-
Authors
Prasad, Kavya
Serencsits, Brian E.
Chu, Bae P.
Dauer, Lawrence T.
Donzelli, Maria
Basu, Ellen
Kramer, Kim
Pandit-Taskar, Neeta http://orcid.org/0000-0003-1551-2036
-
Funding
Funding for this research was provided by:
National Cancer Institute (P30 CA008748)
National Institutes of Health (K08 CA072868, R21 CA089935, R21 CA117076)
Luke’s Lollies (N/A)
Catie Hoch Foundation (N/A)
Y-mAbs (N/A)
- License Information
-
More Information
Article History
Received: 22 February 2024
Accepted: 6 July 2024
First Online: 31 July 2024
Declarations
:
: Ethics approval and consent to participate in human research studies was reviewed and approved by Memorial Sloan Kettering Cancer Center’s Institutional Review Board (IRB). A waiver of informed consent was provided by the IRB 16-1589 titled Patient-specific Radiation Dosimetry for Oncology Radiopharmaceutical and X-Ray Procedures: Retrospective Research Protocol for retrospective studies involving the review of patient-specific dosimetry data. The authors state that they have followed the principles outlined in the Declaration of Helsinki for all human investigations.
: The need for informed consent was waived by the IRB.
: Consent was waived per approved institutional IRB.
: This research was funded in part by NIH/NCI Cancer Center Support Grant P30 CA008748. Y-mAbs, the company licensing the intellectual property from MSK, has provided funding for this study. NPT has served as a consultant or advisory board member for, and/or received honoraria from, Actinium Pharma, Progenics, Medimmune/Astrazeneca, Illumina, and ImaginAb and conducts research institutionally supported by Y-mAbs, ImaginAb, BMS, Bayer, Clarity Pharma, Janssen, and Regeneron. KK has received support from NIH grants K08 CA072868, R21 CA089935, and R21 CA117076, and from Luke’s Lollies and the Catie Hoch Foundation. The other authors have no conflicts of interest to report.
: MSK has institutional financial interests related to this research in the form of intellectual property rights and equity interests in Y-mAbs, the company licensing the intellectual property from MSK. Y-mAbs has provided funding for this study. NPT has served as a consultant or advisory board member for, and/or received honoraria from, Actinium Pharma, Progenics, Medimmune/Astrazeneca, Illumina, and ImaginAb and conducts research institutionally supported by Y-mAbs, ImaginAb, BMS, Bayer, Clarity Pharma, Janssen, and Regeneron. The other authors have no relevant financial or non-financial interests to disclose.
